Teysuno™ will be launched in Europe during the second half of 2011.
About Gastric Cancer
With an estimated 934,000 new cases per year (8.6% of all new cancer cases), gastric cancer is the fourth most common cancer worldwide, following lung, breast, and colorectal cancers. It is the second most common cause of cancer-related death, accounting for an estimated 700,000 to 800,000 deaths annually. Nearly 70% of new cases occur in developing countries; 42% of new cases occur in China alone.
In Europe, gastric cancer is the seventh most common cancer and the sixth most common cause of cancer death, with an estimated annual mortality rate of 118,200. In general, gastric cancer incidence rates are about twice as high among men as in women. The disease is difficult to cure unless it is diagnosed in its early stages. Unfortunately, because early gastric cancer causes few symptoms, the disease is not usually diagnosed until it has reached an advanced stage. In Europe, the five-year survival rate for gastric cancer is roughly 20% in men and 25% in women. Similarly, in the United States, the five-year survival rate for gastric cancer is 24%, though survival rates improve to 61% if the disease is detected early. However, less than one-quarter of gastric cancers are diagnosed at an early stage in the United States. In contrast, the five-year survival rate exceeds 50% in Japan, where early gastric cancer is diagnosed relatively frequently due to mass screening efforts, which have been practiced since the 1960s.
Teysuno™ was authorized for the treatment of gastric cancer in Japan in 1999. Teysuno™ is also authorized for patients with gastric cancer in South Korea, China, Singapore and Taiwan. To date, Teysuno™ has been used by more than 870,000 patients in Japan and Asia.
|SOURCE Taiho Pharmaceutical Co., Ltd.|
Copyright©2010 PR Newswire.
All rights reserved